SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+24.18%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$840M
AUM Growth
+$840M
(+39%)
Cap. Flow
+$94.3M
Cap. Flow
% of AUM
11.22%
Top 10 Holdings %
Top 10 Hldgs %
49.44%
Holding
116
New
35
Increased
16
Reduced
23
Closed
30
Top Buys
| 1 |
AbbVie
ABBV
|
$55.9M |
| 2 |
Nice
NICE
|
$24.5M |
| 3 |
Amgen
AMGN
|
$18.9M |
| 4 |
AstraZeneca
AZN
|
$16.9M |
| 5 |
Eli Lilly
LLY
|
$14.8M |
Top Sells
| 1 |
Larimar Therapeutics
LRMR
|
$35.5M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$22.4M |
| 3 |
Sarepta Therapeutics
SRPT
|
$21.6M |
| 4 |
Pfizer
PFE
|
$18M |
| 5 |
Novo Nordisk
NVO
|
$11.5M |
Sector Composition
| 1 | Healthcare | 81.38% |
| 2 | Technology | 10.39% |
| 3 | Consumer Discretionary | 2.06% |
| 4 | Industrials | 1.78% |
| 5 | Communication Services | 1.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Zymeworks
ZYME
$1.12B
| $4.2M | 0.39% | 116,310 -90,520 | -44% | -$3.26M |
|
|
ORGS
52
DELISTED
Orgenesis Inc. Common Stock
ORGS
| $4.05M | 0.38% | 665,767 -443,797 | -40% | -$2.7M |
|
|
ARYAU
53
DELISTED
ARYA Sciences Acquisiton Corp. Unit
ARYAU
| $4M | 0.38% | 200,000 | – | – |
|
|
ARYBU
54
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
| $3.48M | 0.33% | +300,000 | New | +$3.48M |
|
55
Catalyst Pharmaceutical
CPRX
$2.52B
| $3.38M | 0.32% | +730,557 | New | +$3.38M |
|
|
GRTX
56
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $3.35M | 0.32% | 469,245 -6,432 | -1% | -$45.9K |
|
57
Enphase Energy
ENPH
$4.93B
| $3.33M | 0.31% | +70,000 | New | +$3.33M |
|
58
Syndax Pharmaceuticals
SNDX
$1.41B
| $3.26M | 0.31% | 220,000 +151,866 | +223% | +$2.25M |
|
59
Wave Life Sciences
WVE
$1.53B
| $3.05M | 0.29% | +293,000 | New | +$3.05M |
|
60
Compugen
CGEN
$132M
| $3M | 0.28% | +200,000 | New | +$3M |
|
61
KalVista Pharmaceuticals
KALV
$678M
| $2.91M | 0.27% | 240,140 | – | – |
|
62
Perrigo
PRGO
$3.27B
| $2.76M | 0.26% | +50,000 | New | +$2.76M |
|
63
Soleno Therapeutics
SLNO
$3.6B
| $2.74M | 0.26% | +1,233,676 | New | +$2.74M |
|
64
Immunovant
IMVT
$2.56B
| $2.56M | 0.24% | 105,000 +85,968 | +452% | +$2.09M |
|
65
argenx
ARGX
$43.6B
| $2.31M | 0.22% | 10,265 | – | – |
|
|
AKUS
66
DELISTED
Akouos, Inc. Common Stock
AKUS
| $2.25M | 0.21% | +100,000 | New | +$2.25M |
|
67
Akebia Therapeutics
AKBA
$833M
| $2.11M | 0.2% | +155,000 | New | +$2.11M |
|
68
Leap Therapeutics
LPTX
$12M
| $1.84M | 0.17% | 880,000 +280,000 | +47% | +$585K |
|
69
MEI Pharma
MEIP
$160M
| $1.69M | 0.16% | +410,000 | New | +$1.69M |
|
70
Viking Therapeutics
VKTX
$3.04B
| $1.48M | 0.14% | 205,000 -385,000 | -65% | -$2.78M |
|
|
NBSE
71
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $1.32M | 0.12% | +150,000 | New | +$1.32M |
|
72
Immunic
IMUX
$80.9M
| $1.21M | 0.11% | +100,000 | New | +$1.21M |
|
|
ISEE
73
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $1.02M | 0.1% | 200,000 +76,576 | +62% | +$391K |
|
|
BLU
74
DELISTED
BELLUS Health Inc.
BLU
| $1.01M | 0.09% | +97,805 | New | +$1.01M |
|
|
NEOS
75
DELISTED
Neos Therapeutics, Inc
NEOS
| $651K | 0.06% | 950,311 -1,559,157 | -62% | -$1.07M |
|